Biomarkers in Breast Cancer

Molecular Diagnostics for Predicting and Monitoring Therapeutic Effect

  • Giampietro Gasparini
  • Daniel F. Hayes

Part of the Cancer Drug Discovery and Development book series (CDD&D)

Table of contents

  1. Front Matter
    Pages i-xi
  2. General Topics

  3. Assays for Gene Expression and Post-Translational Protein Abnormalities

    1. Front Matter
      Pages 45-45
    2. Michele De Bortoli, Nicoletta Biglia
      Pages 47-61
  4. Assays for DNA Abnormalities

    1. Front Matter
      Pages 63-63
    2. Chungyeul Kim, Yongkuk Song, Soonmyung Paik
      Pages 65-77
  5. Tissue Predictive Biomakers

    1. Front Matter
      Pages 79-79
    2. Maria Grazia Daidone, Rosella Silvestrini, Dino Amadori
      Pages 81-109
    3. Michael J. Duffy
      Pages 111-128
    4. Robert Mass
      Pages 159-175
    5. Daniela Kandioler, Raimund Jakesz
      Pages 193-209
  6. Predictive Biomarkers in Body Fluids

    1. Front Matter
      Pages 211-211
    2. Stephan Braun, Julia Seeber, Christian Marth
      Pages 213-233
    3. Allan Lipton, Laurence Demers, Kim Leitzel, Suhail M. Ali, Rainer Neumann, Christopher P. Price et al.
      Pages 235-265
    4. Roberta Sarmiento, Roberta Franceschini, Sabrina Meo, Massimo Gion, Raffele Longo, Giampietro Gasparini
      Pages 267-292
  7. Future Directions

    1. Front Matter
      Pages 323-323
    2. Daniel F. Hayes, Giampietro Gasparini
      Pages 325-331
  8. Back Matter
    Pages 333-341

About this book


It is now well recognized that individualized cancer treatment planning, based on tumor characteristics specific to an individual's cancer, makes it easier to select those most likely to benefit from toxic cancer therapies and to avoid treating those least likely to benefit. In Biomarkers in Breast Cancer: Molecular Diagnostics for Predicting and Monitoring Therapeutic Effect, expert laboratory and clinical researchers from around the world review how to design and evaluate studies of tumor markers, as well as examine their use in breast cancer patients. The authors cover both the major advances in sophisticated molecular methods and the state-of-the-art in conventional prognostic and predictive indicators. Among the topics discussed are the relevance of rigorous study design and guidelines to the validation of new biomarkers, gene expression profiling by tissue microarrays, adjuvant systemic therapy, and the use of estrogen, progesterone, and epidermal growth factor receptors as both prognostic and predictive indicators. Highlights include the evaluation of HER2 and EGFR family members, of p53, and of UPA/PAI-1; the detection of rare cells in blood and marrow; and the detection and analysis of soluble, circulating markers.
Authoritative and cutting-edge, Biomarkers in Breast Cancer: Molecular Diagnostics for Predicting and Monitoring Therapeutic Effect offers laboratory investigators developing new tumor markers, clinical investigators testing them, and clinicians using them an up-to-date understanding of both the prognostic/predictive indicators and the novel molecular-targeted therapies suitable for individualizing breast cancer therapy.


DNA classification gene expression systemic therapy translation

Editors and affiliations

  • Giampietro Gasparini
    • 1
  • Daniel F. Hayes
    • 2
  1. 1.Division of Medical Oncology“San Filippo Neri” HospitalRomeItaly
  2. 2.Breast Oncology ProgramUniversity of Michigan Comprehensive Cancer CenterAnn Arbor

Bibliographic information

Industry Sectors
Health & Hospitals
Oncology & Hematology
Consumer Packaged Goods